Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)

Annals of Hematology ◽

10.1007/s00277-011-1240-1 ◽

2011 ◽

Vol 91 (1) ◽

pp. 33-38 ◽

Author(s):

Amanda Cashen ◽

Mark Juckett ◽

Alcee Jumonville ◽

Mark Litzow ◽

P. J. Flynn ◽

...

Keyword(s):

Myelodysplastic Syndrome ◽

Histone Deacetylase ◽

Phase Ii ◽

Histone Deacetylase Inhibitor ◽

Phase Ii Study ◽

Deacetylase Inhibitor

Download Full-text

Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome

American Journal of Hematology ◽

10.1002/ajh.22198 ◽

2011 ◽

Vol 87 (1) ◽

pp. 127-129 ◽

Author(s):

Sophie Dimicoli ◽

Elias Jabbour ◽

Gautam Borthakur ◽

Tapan Kadia ◽

Zeev Estrov ◽

...

Keyword(s):

Myelodysplastic Syndrome ◽

Histone Deacetylase ◽

Phase Ii ◽

Histone Deacetylase Inhibitor ◽

Phase Ii Study ◽

Deacetylase Inhibitor

Download Full-text

A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas—NCIC-CTG IND 200

Annals of Oncology ◽

10.1093/annonc/mdv033 ◽

2015 ◽

Vol 26 (5) ◽

pp. 973-981 ◽

Author(s):

Q. S.-C. Chu ◽

T.O. Nielsen ◽

T. Alcindor ◽

A. Gupta ◽

M. Endo ◽

...

Keyword(s):

Histone Deacetylase ◽

Phase Ii ◽

Histone Deacetylase Inhibitor ◽

Phase Ii Study ◽

Deacetylase Inhibitor

Download Full-text

A Phase II Study of the Histone Deacetylase Inhibitor, Vorinostat, in Combination with Trastuzumab in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent HER-2 Amplified Breast Cancer Resistant to Transtuzumab-Containing Therapy: (E1104) a Trial of the Eastern Cooperative Oncology Group.

10.1158/0008-5472.sabcs-09-5084 ◽

2009 ◽

Author(s):

R. Swaby ◽

M. Wang ◽

J. Sparano ◽

K. Bhalla ◽

N. Meropol ◽

...

Keyword(s):

Breast Cancer ◽

Histone Deacetylase ◽

Phase Ii ◽

Histone Deacetylase Inhibitor ◽

Phase Ii Study ◽

Eastern Cooperative Oncology Group ◽

Oncology Group ◽

Deacetylase Inhibitor ◽

Download Full-text

A Phase II Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Pretreated Patients with Small-Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1097/jto.0b013e318293d88c ◽

2013 ◽

Vol 8 (8) ◽

pp. 1091-1094 ◽

Author(s):

Filippo de Marinis ◽

Akin Atmaca ◽

Marcello Tiseo ◽

Libero Giuffreda ◽

Antonio Rossi ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Histone Deacetylase ◽

Phase Ii ◽

Histone Deacetylase Inhibitor ◽

Phase Ii Study ◽

Small Cell Lung ◽

Deacetylase Inhibitor ◽

Pretreated Patients

Download Full-text

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

Breast Diseases A Year Book Quarterly ◽

10.1016/j.breastdis.2012.01.036 ◽

2012 ◽

Vol 23 (1) ◽

pp. 88-89

Author(s):

D. Tripathy ◽

E. Thara

Keyword(s):

Breast Cancer ◽

Hormone Therapy ◽

Histone Deacetylase ◽

Phase Ii ◽

Histone Deacetylase Inhibitor ◽

Phase Ii Study ◽

Deacetylase Inhibitor

Download Full-text

Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma

Journal of Thoracic Oncology ◽

10.1097/jto.0b013e318191520c ◽

2009 ◽

Vol 4 (1) ◽

pp. 97-101 ◽

Author(s):

Suresh S. Ramalingam ◽

Chandra P. Belani ◽

Christopher Ruel ◽

Paul Frankel ◽

Barbara Gitlitz ◽

...

Keyword(s):

Histone Deacetylase ◽

Phase Ii ◽

Malignant Pleural Mesothelioma ◽

Histone Deacetylase Inhibitor ◽

Phase Ii Study ◽

Pleural Mesothelioma ◽

Second Line ◽

Second Line Therapy ◽

Line Therapy ◽

Deacetylase Inhibitor

Download Full-text

Phase II study of the histone-deacetylase inhibitor ITF2357 in relapsed/refractory Hodgkin’s lymphoma patients

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.8532 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 8532-8532 ◽

Author(s):

S. Viviani ◽

V. Bonfante ◽

C. Fasola ◽

P. Valagussa ◽

A. M. Gianni

Keyword(s):

Histone Deacetylase ◽

Phase Ii ◽

Histone Deacetylase Inhibitor ◽

Hodgkin’S Lymphoma ◽

Phase Ii Study ◽

Hodgkin's Lymphoma ◽

Deacetylase Inhibitor

Download Full-text

Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia

British Journal of Haematology ◽

10.1111/j.1365-2141.2009.07881.x ◽

2009 ◽

Vol 147 (4) ◽

pp. 507-514 ◽

Author(s):

Kristie A. Blum ◽

Anjani Advani ◽

Louis Fernandez ◽

Richard Van Der Jagt ◽

Joseph Brandwein ◽

...

Keyword(s):

Chronic Lymphocytic Leukaemia ◽

Histone Deacetylase ◽

Phase Ii ◽

Histone Deacetylase Inhibitor ◽

Lymphocytic Leukaemia ◽

Phase Ii Study ◽

Deacetylase Inhibitor ◽

Previously Treated

Download Full-text

AT-33A PHASE II STUDY OF CONCURRENT RADIATION THERAPY, TEMOZOLOMIDE AND THE HISTONE DEACETYLASE INHIBITOR VALPROIC ACID FOR PATIENTS WITH GLIOBLASTOMA MULTIFORME

Neuro-Oncology ◽

10.1093/neuonc/nou237.33 ◽

2014 ◽

Vol 16 (suppl_5) ◽

pp. v15-v16 ◽

Author(s):

Andra V. Krauze ◽

Sten D. Myrehaug ◽

Michael G. Chang ◽

Diane J. Holdford ◽

Sharon Smith ◽

...

Keyword(s):

Valproic Acid ◽

Radiation Therapy ◽

Glioblastoma Multiforme ◽

Histone Deacetylase ◽

Phase Ii ◽

Histone Deacetylase Inhibitor ◽

Phase Ii Study ◽

Deacetylase Inhibitor

Download Full-text

Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium – an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879

Investigational New Drugs ◽

10.1007/s10637-020-01038-6 ◽

2021 ◽

Author(s):

David I. Quinn ◽

Denice D. Tsao-Wei ◽

Przemyslaw Twardowski ◽

Ana M. Aparicio ◽

Paul Frankel ◽

...

Keyword(s):

Transitional Cell Carcinoma ◽

Cell Carcinoma ◽

Histone Deacetylase ◽

Phase Ii ◽

Histone Deacetylase Inhibitor ◽

Hydroxamic Acid ◽

Phase Ii Study ◽

Transitional Cell ◽

Suberoylanilide Hydroxamic Acid ◽

Deacetylase Inhibitor

Download Full-text